RT Journal Article
SR Electronic
T1 Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 923
OP 928
DO 10.21873/anticanres.14025
VO 40
IS 2
A1 YUKIKO NAKAMURA
A1 KAZUHITO MIYAZAKI
A1 NAOTO AIKO
A1 YUKI MISUMI
A1 YOKO AGEMI
A1 YURI TANIGUCHI
A1 MARI ISHI
A1 TSUNEO SHIMOKAWA
A1 HIROAKI OKAMOTO
A1 TAKEHARU YAMANAKA
YR 2020
UL http://ar.iiarjournals.org/content/40/2/923.abstract
AB Background/Aim: We assessed the efficacy of immune checkpoint inhibitors (ICIs) in older patients because of the limited information regarding these patients. Patients and Methods: We retrospectively analyzed 66 consecutive patients ≥70 years old with advanced non-small cell lung cancer (NSCLC). A total of 31 patients received ICIs (ICIs group) and 35 patients received only cytotoxic regimens (No ICIs group). Results: Patients with squamous cell carcinoma who received ICIs had better overall survival (OS) than those who did not (9.7 versus 4.7 months, p=0.027). In multivariate analysis, treatment with ICIs [hazard ratio (HR)=0.54, 95% confidence interval (CI)=0.30-0.98, p=0.044], good performance status (HR=0.30, 95%CI=0.16-0.57, p=0.0003), and histology other than squamous cell carcinoma (HR=0.41, 95%CI=0.19-0.83, p=0.014) were significantly favorable factors for OS. Conclusion: ICIs may be effective for older patients with NSCLC, especially squamous cell carcinoma patients.